MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 41 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,684 | -18.5% | 6,787 | -18.7% | 0.00% | – |
| Q2 2023 | $102,631 | +2565675.0% | 8,344 | +2257.1% | 0.00% | – |
| Q4 2022 | $4 | -99.9% | 354 | -32.6% | 0.00% | – |
| Q2 2021 | $3,000 | – | 525 | +7400.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 7 | -99.0% | 0.00% | – |
| Q2 2020 | $2,000 | -91.7% | 681 | -93.9% | 0.00% | – |
| Q1 2020 | $24,000 | -27.3% | 11,157 | +7.0% | 0.00% | – |
| Q4 2019 | $33,000 | – | 10,425 | +10325.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $1,000 | -99.6% | 100 | -99.7% | 0.00% | – |
| Q1 2019 | $232,000 | +7.4% | 33,370 | -40.3% | 0.00% | – |
| Q4 2018 | $216,000 | -26.5% | 55,934 | +1.5% | 0.00% | – |
| Q3 2018 | $294,000 | – | 55,094 | +54994.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 100 | -96.7% | 0.00% | – |
| Q1 2018 | $25,000 | -21.9% | 3,039 | -4.3% | 0.00% | – |
| Q4 2017 | $32,000 | +700.0% | 3,177 | +892.8% | 0.00% | – |
| Q3 2017 | $4,000 | – | 320 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Standard LLC | 1,894,013 | $23,353,180 | 21.09% |
| Newtyn Management, LLC | 1,873,694 | $23,102,647 | 5.70% |
| Sio Capital Management, LLC | 288,466 | $3,556,786 | 1.10% |
| Madison Avenue Partners, LP | 553,085 | $6,819,538 | 0.97% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 209,739 | $2,586 | 0.95% |
| Indaba Capital Management, L.P. | 136,802 | $1,686,769 | 0.50% |
| Sepio Capital, LP | 306,680 | $3,781,364 | 0.33% |
| Yakira Capital Management, Inc. | 54,118 | $667,275 | 0.18% |
| Centiva Capital, LP | 187,803 | $2,315,611 | 0.05% |
| FIFTH LANE CAPITAL, LP | 10,929 | $134,427 | 0.05% |